首页> 外文期刊>Journal of Pharmaceutical Policy and Practice >Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we?
【24h】

Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we?

机译:蒙古不良药物反应报告的立法及目前发展:我们有多远?

获取原文
       

摘要

Abstract Monitoring adverse drug reactions is a vital issue to ensure drug safety and to protect the general public from medication-related harmful effects. In order to properly monitor drug safety, a regulatory system needs to be in place as well as an infrastructure that allows for analyzing national and international safety data. In Mongolia, adverse drug reaction (ADR) reporting activities have been implemented in the past decade. During this period, the basic structure and legal basis of an adverse drug reaction monitoring system was established. Because of the fragmented but growing healthcare system and the complexity of pharmaceutical issues in Mongolia, a sustainable process for the development of the adverse drug reaction reporting system is a key issue. The aim of this article is to disclose the Mongolian situation for the rest of the world and to share experiences on how an ADR reporting system can be developed towards a higher and more advanced level to contribute to both national and international drug safety issues. In this article, we review the?features of the Mongolian health care and pharmaceutical systems, as well as the?current development of the adverse drug reaction reporting system.
机译:摘要监测不良药物反应是确保药物安全性,并保护公众免受与药物相关的有害影响保护的重要问题。为了正确监控药物安全,需要进行监管系统以及基础设施,允许分析国家和国际安全数据。在蒙古,过去十年已实施不良药物反应(ADR)报告活动。在此期间,建立了不良药物反应监测系统的基本结构和法律依据。由于碎片但不断增长的医疗保健制度以及蒙古药物问题的复杂性,因此,对不良药物反应报告系统的可持续发展过程是关键问题。本文的目的是披露世界其他地区的蒙古局势,并分享关于ADR报告系统如何发展到更高且更先进的水平,以促进国家和国际药物安全问题。在本文中,我们审查了蒙古医疗保健和制药系统的特征,以及当前的不良药物反应报告系统的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号